Skip to main content

Vin Miles, Jeff Vick, Iain Ross, Jeremy Curnock Cook

Dicerna Pharmaceuticals said this week that Vin Miles has joined its board of directors.
Miles is currently a venture partner at life sciences investment group Abingworth. Prior to this, he served as senior vice president of business development for RNAi drug shop Alnylam Pharmaceuticals.
Abingworth was an early investor in Alnylam.
“Miles’ deep operating experience in the biotechnology industry and familiarity with RNAi is a tremendous asset and complement to our existing capabilities,” Dicerna CEO and Co-founder Jim Jenson said in a statement.

Silence Therapeutics said this week that CEO Jeff Vick has resigned for “personal reasons.”
The company said its board has now appointed Iain Ross, non-executive chairman, as the full-time chairman and CEO.
Silence also said that Jeremy Curnock Cook, a non-executive director, has been named senior independent non-executive director.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.